Log in
Enquire now
Recolony AG

Recolony AG

Recolony is a Swiss biotech start-up with the goal of developing a bacteria-based oral therapy to treat and prevent cancer.

OverviewStructured DataIssuesContributors

All edits by  Мария Пронькина 

Edits on 9 Feb, 2023
Мария Пронькина profile picture
Мария Пронькина
edited on 9 Feb, 2023
Edits made to:
Infobox (+11/-1 properties)
Description (+123 characters)
Topic thumbnail

Recolony AG

Recolony is a Swiss biotech start-up with the goal of developing a bacteria-based oral therapy to treat and prevent cancer.

Infobox
Is a
Organization
Organization
Official Website
https://www.recolony.ch/
Location
Zürich
Zürich
0
Industry
Biotechnology
Biotechnology
Twitter URL
https://twitter.com/RecolonyAG
LinkedIn URL
https://www.linkedin.com/company/recolony/
CEO
Ana Montalban-Arques, PhD
Ana Montalban-Arques, PhD
0
Email Address
info@recolony.ch0
Founder
Ana Montalban-Arques, PhD
Ana Montalban-Arques, PhD
0
Philipp Busenhart, PhD
Philipp Busenhart, PhD
0
Eglė Katkevičiūtė, PhD
Eglė Katkevičiūtė, PhD
0
Full Address
Weinbergstrasse 35 WEH F-Floor 8092 Zurich Switzerland0
"Created via: Web app"
Мария Пронькина profile picture
Мария Пронькина
created this topic on 9 Feb, 2023
Edits made to:
Infobox (+1 properties)
Topic thumbnail

 Recolony AG

Recolony is a Swiss biotech start-up with the goal of developing a bacteria-based oral therapy to treat and prevent cancer.

Infobox
Is a
Company
Company

Find more companies like Recolony AG

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.